Serum institute of india logo

GAITHERSBURG, Md.and PUNE, India, Jan. 10, 2022 /PRNewswire/ --Novavax, Inc. (Nasdaq: South Africa under the brand name Covovax™. "Novavax is thankful for our long-standing history of partnership in South Africa to advance much-needed vaccines. This is exemplified by the country's vital role in the Phase 2b clinical trial and booster study of our protein-based COVID-19 vaccine," said Stanley C. Erck, President and Chief Executive Officer, Novavax. "Novavax and Serum Institute remain focused on delivering the COVID-19 vaccine - built on well-understood technology - where it is needed most. We look forward to SAHPRA's review and, if authorized, delivering the vaccine to help South Africa control the pandemic." The submission for the regulatory evaluation by SAHPRA of NVX-CoV2373 includes data from two pivotal Phase 3 clinical trials: PREVENT-19, which enrolled approximately 30,000 participants in the U.S. and Mexico and was published in the Novavax’ vaccine has received conditional marketing authorization (CMA) for its vaccine in the For more information on NVX-CoV2373, including a full listing of where it has been authorized for use, please visit Novavax' Important Safety Information • NVX-CoV2373 is contraindicated in persons who have a hypersensitivity to the active substance, or to any of the excipients. • Events of anaphylaxis have been reported with administration of COVID-19 vaccines. Appropriate medical treatment and supervision should be available in case of an anap...

DTaP Vaccine Serum Institute of India has initiated development of acellular pertussis vaccine containing purified antigenic components of B. Pertussis viz. Pertussis Toxoid (PT), Filamentous Haemagglutinin (FHA), Pertactin. The DTaP vaccine that is under development at Serum Institute of India is being tested at NIBSC, UK and is undergoing toxicology studies. Serum Institute of India plans to develop this product for the people of the developing world within next two years. DTP vaccines in the near future will have combinations of other components and the key antigen for such combinations will be acellular pertussis component. Pentavalent Meningococcal Conjugate Vaccine (A, C, Y, W-135, X) Serum Institute of India is working on a thermostable Pentavalent Meningococcal Conjugate Vaccine (A, C, Y, W-135, X) for developing countries. The Institute is already involved with WHO and PATH to prevent and ultimately eliminate epidemic group A meningococcal disease in the African meningitis belt. Consequently, the Institute is ideally placed to develop this new Pentavalent Conjugate Vaccine and deliver a safe and effective product at an affordable price to the parts of the world where it is needed most. ErepoXen (Polysialylated Erythropoietin) Serum Institute of India is developing ErepoXen product candidate, which is an enhanced polysialylated form of erythropoietin, a hormone produced by the kidneys to maintain red blood cell production and prevent anaemia caused by chronic kidne...

MUMBAI, India, November 20, 2014 /PRNewswire/ -- Cipla Europe NV ("Cipla"), a global pharmaceutical company is delighted to announce that it has signed a distribution agreement with Serum Institute of India Ltd. (SII) - a global leader in the production of vaccines. Under the agreement, SII will develop and manufacture paediatric vaccines, Cipla will seek European Medicines Agency approval and market the products in Europe. This collaboration with SII enables Cipla to enter into the vaccines segment, continuing our commitment to inclusive healthcare for the world. The vaccines will be manufactured in Serum's world class production facilities approved by WHO. (Logo: Commenting on the collaboration, Mr. Subhanu Saxena, MD & Global CEO, Cipla Limited said: "We are proud to have entered into a strategic Europe-specific partnership with Serum Institute of India. This collaboration is aligned with our commitment to access to affordable paediatric healthcare. Both Cipla and SII share the same core values such as self-sufficiency, affordability, accessibility, quality and commitment to global health. Through this partnership, we look forward to contribute in eradication of childhood diseases." Mr. Adar Poonawalla, CEO and Executive Director, SII said: "Serum Institute believes that this tie-up with Cipla is a perfect platform for making vaccines available for Europeans as Serum also shares the common philosophy of Cipla of making vaccines/pharmaceutical products available at the m...

• Thursday, April 13, 2023 R21/Matrix-M™ malaria vaccine developed by University of Oxford & SII receives regulatory clearance for use in Ghana ... • Tuesday, January 24, 2023 Serum Institute Of India launches the first made-in-India qHPV vaccine 'CERVAVAC' ... • Thursday, December 15, 2022 Oxford Ebola vaccine manufactured and shipped in record time by Serum Institute Of India ... • Thursday, September 01, 2022 Department of Biotechnology announces the scientific completion of India's first qHPV vaccine 'CERVAVAC' ...

• Home • Company • Company • Vision & Mission • Code of Conduct • Quality Policy • Our Leadership • Our Advisors • Advisory Board • CSR • Careers • Sciences • Diseases • COVID-19 • Pertussis • Influenza • Research & Development • R&D Pipeline • R&D SARS-CoV-2 • Products • Product Portfolio • Marketing Network • Partnerships • R&D Collaborations • Technology-Transfer • Market Reach • Our Partners • News • All News • BioNet News • Biotech News • Press Releases • Contact Serum Institute of India is ranked as India’s No. 1 biotechnology Serum Institute of India was founded in 1966 by Dr. Cyrus Poonawalla with the aim of manufacturing life-saving immuno-biologicals, which were in shortage in the country and imported at high prices. Thereafter, several life-saving biologicals were manufactured at prices affordable to the common man and in abundance, with the result that the country was made self-sufficient for Tetanus Anti-toxin and Anti-snake Venom serum, followed by DTP (Diphtheria, Tetanus and Pertussis) group of Vaccines and then later on MMR (Measles, Mumps and Rubella) group of vaccines. The Philanthropic philosophy of the company still not only exists but has been proliferated to bring down the prices of newer vaccines such as Hepatitis-B vaccine, Combination vaccine etc., so that not only Indian’s, but the entire under-privileged children of the world are protected from birth onwards. Serum Institute of India has established the most modern laboratories with high-tech ma...